Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Debra Frye"'
Autor:
Ozlem Er, Shu-Wan C Kau, Vicente Valero, Banu Arun, Gabriel N. Hortobagyi, Debra Frye, Kristine Broglio
Publikováno v:
The Cancer Journal. 14:62-68
Purpose: The purpose of this retrospective analysis was to describe the clinical course of patients with breast cancer with liver metastases alone who were treated on doxorubicin/cyclophosphamide or taxane-containing chemotherapy protocols at the M.
Autor:
Aman U. Buzdar, William Fraser Symmans, Thomas A. Buchholz, Lajos Pusztai, Gabriel N. Hortobagyi, S. W. Kau, Henry Mark Kuerer, Karen O. Anderson, A. M. Gonzalez-Angulo, Kenneth R. Hess, Debra Frye, Fabrice Andre, Chafika Mazouni
Publikováno v:
Annals of Oncology. 18:874-880
Background: We examined if inclusion of a taxane and more prolonged preoperative chemotherapy improves pathologic complete response (pCR) rate in estrogen receptor (ER)-positive breast cancer compared with three to four courses of 5-fluorouracil, dox
Autor:
Debra Frye, Marguerite Rosales, Massimo Cristofanilli, Edgardo Rivera, Daniel J. Booser, Vicente Valero, Gabriel N. Hortobagyi
Publikováno v:
Cancer. 94:2321-2326
PURPOSE The authors conducted a single-institution Phase I clinical trial to determine the maximum tolerated doses and to define the toxic effects of oral eniluracil and oral 5-fluorouracil (5-FU) combined with docetaxel in patients with metastatic b
Autor:
S. Eva Singletary, Lina Asmar, Richard L. Theriault, Daniel J. Booser, Aman U. Buzdar, Gabriel N. Hortobagyi, Vicente Valero, Marsha D. McNeese, Debra Frye, Paulo M. Hoff
Publikováno v:
Cancer. 88:2054-2060
BACKGROUND The purpose of the current study was to evaluate the objective response rate and possibility of breast-conserving surgery using neoadjuvant tamoxifen in the multimodality treatment, including surgery and radiotherapy, of elderly or frail p
Autor:
Frederick C. Ames, Eric A. Strom, Sonja E. Singletary, Gabriel N. Hortobagyi, Frankie A. Holmes, Nour Sneige, Sergio Giralt, Gabriela Rondon, Issa F. Khouri, Albert B. Deisseroth, Debra Frye, Daniel J. Booser, Vicente Valero, Richard L. Theriault, Terry L. Smith, Aman U. Buzdar, James Gajewski, Borje S. Andersson, Marsha D. McNeese, Richard E. Champlin
Publikováno v:
JNCI: Journal of the National Cancer Institute. 92:225-233
Background: Uncontrolled studies have reported encouraging outcomes for patients with high-risk primary breast cancer treated with high-dose chemotherapy and autologous hematopoietic stem cell support. We conducted a prospective randomized trial to c
Autor:
Kapil Dhingra, Edgardo Rivera, Aman U. Buzdar, Debra Frye, Giuseppe Fraschini, Daniel J. Booser, Gabriel N. Hortobagyi, Vicente Valero, Richard L. Theriault, Ronald S. Walters, Frankie A. Holmes
Publikováno v:
Cancer. 89:2195-2201
BACKGROUND The authors conducted a single institution Phase II clinical trial to determine whether paclitaxel had antitumor activity in patients with metastatic breast carcinoma that was refractory to standard chemotherapy. METHODS Patients with meta
Autor:
Terry L. Smith, Gabriel N. Hortobagyi, Z. Rahman, E. A. Diaz-Canton, Vicente Valero, E. Rodriguez-Monge, Debra Frye, Aman U. Buzdar
Publikováno v:
Annals of Oncology. 9:413-418
Summary Purpose To evaluate the clinical course of patients with a metastatic breast cancer (MBC) confined to the lungs and treated with doxorubicin/cyclophosphamide-containing chemotherapy (DC-CT). Patients and methods Between 1973 and 1985, 1581 pa
Autor:
Ralph F. Frankowski, Anita Y. Kinney, Gabriel N. Hortobagyi, Sally W. Vernon, Debra Frye, John F. Annegers, Aysegul A. Sahin, Aman U. Buzdar, Kapil Dhingra
Publikováno v:
Cancer. 80:2240-2249
BACKGROUND Sialyl-Tn (STn) represents an aberrantly glycosylated mucin epitope that is expressed in breast carcinoma and other adenocarcinomas and is an important factor in the development of novel immunotherapeutic approaches. The primary aim of the
Autor:
Lina Asmar, Debra Frye, Terry L. Smith, Gabriel N. Hortobagyi, Z. Rahman, Richard E. Champlin, Aman U. Buzdar
Publikováno v:
Journal of Clinical Oncology. 15:3171-3177
PURPOSE Most of the data about high-dose chemotherapy (HDCT) for metastatic breast cancer are derived from phase II studies. The interpretation of these data depends on comparisons with data from properly selected historical control patients treated
Publikováno v:
The Breast. 5:312-317
First-line chemotherapy for matastatic breast cancer extends median survival by 9–12 months. A small fraction of patients achieve long-term remission with standard chemotherapy. With second-line chemotherapies, there is an objective response of 25